Hormone therapy not tied to breast cancer recurrence, mortality
No increased risk seen for women using either vaginal oestrogen therapy or menopausal hormone therapy after diagnosis
In postmenopausal women treated for early-stage oestrogen receptor-positive breast cancer, neither vaginal oestrogen therapy nor menopausal hormone therapy is associated with an increased risk for recurrence or mortality, according to a study published online on 20 July in the Journal of the National Cancer Institute.
Søren Cold, MD, from Odense University in Denmark, and colleagues used longitudinal data from a national cohort of postmenopausal women, diagnosed in 1997 to 2004 with early-stage invasive oestrogen receptor-positive nonmetastatic breast cancer.
